AstraZeneca PLC
AZN
Positions held
Your positionsAZN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- AstraZeneca's strong revenue growth of 6.4% year-over-year indicates a robust demand for its innovative therapies in a competitive healthcare market.
- In Q2 2026, AstraZeneca reported a revenue of $15.384 billion, a slight increase of 1% from the previous quarter.
- The company's gross margin improved to 83.6% in Q2 2026, up from 82.5% in Q1 2026.
- The company's current ratio of 0.886 suggests potential liquidity issues, which could hinder its ability to meet short-term obligations.
- AstraZeneca's operating margin decreased to 20.6% in Q2 2026, indicating potential challenges in managing operational efficiency.
- The stock has a strong sell signal with a score of -32.00, reflecting negative trends in market performance.
Fundamentals
| Market cap | $246.25B | Enterprise value | $273.72B | Trailing P/E | 23.73 | Forward P/E | 13.73 |
| PEG | 1.13 | Price / book | 4.90 | Beta | 0.21 | Dividend yield | 2.02% |
| Revenue growth | 6.4% | Earnings growth | 2.5% | Gross margin | 81.7% | Operating margin | 23.5% |
| Profit margin | 17.0% | ROE | 22.0% | ROA | 8.2% | Debt / equity | 0.64 |
| Current ratio | 0.89 | Free cash flow | $5.12B | Analyst recommendation | buy | Mean target | $206.91 |
| 52w high | $212.71 | 52w low | $153.41 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $15.4B | $15.3B | $15.5B | $15.2B | $14.5B | — |
| Op margin | 20.6% | 27.8% | 19.2% | 23.6% | 24.3% | — |
| Net income | $2.5B | $3.1B | $2.3B | $2.5B | $2.5B | — |
| Gross margin | 83.6% | 82.5% | 79.9% | 81.6% | 82.9% | — |
| Gross profit | $12.9B | $12.6B | $12.4B | $12.4B | $12.0B | — |
| Operating income | $3.2B | $4.2B | $3.0B | $3.6B | $3.5B | — |
- Revenue +1% vs prior quarter ($15.4B vs $15.3B).
- Gross margin 83.6% (was 82.5% prior quarter).
- Operating margin compressed to 20.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $58.7B | $54.1B | $45.8B | $44.4B | — |
| Op margin | 22.7% | 19.0% | 19.0% | 10.2% | — |
| Net income | $10.2B | $7.0B | $6.0B | $3.3B | — |
| Gross margin | 81.9% | 81.1% | 82.0% | 72.1% | — |
| Gross profit | $48.1B | $43.9B | $37.5B | $32.0B | — |
| Operating income | $13.3B | $10.3B | $8.7B | $4.5B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Guardant Gets European Approval for Guardant360 as Companion Diagnostic for AstraZeneca's Etcamah in Breast Cancer
2026-10-08 · AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?
2026-10-08 · Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results
2026-10-08 · Pharma’s $500B patent problem will come in waves — not as a cliff
2026-10-08 · How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
2026-10-08 · Astrazeneca, Daiichi Sankyo's Breast Cancer Drug Approved in China
2026-10-07 · Health Care Roundup: Market Talk
Price (daily)
Full chart · RSI · MACD · patterns